The Cochlear share price just hit an all-time high: Too late to invest?

The Cochlear Limited (ASX:COH) share price just hit an all-time high. Is it too late to buy this healthcare star?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price continued its positive form on Tuesday and climbed to a new all-time high of $226.71.

When the hearing solutions company's shares hit this level it meant they had gained an impressive 30% since the start of the year.

Why is the Cochlear share price at an all-time high?

As well as benefiting from positive market sentiment, investors have been bidding up Cochlear's shares due to its strong performance during the first half of FY 2019 and its positive long term outlook.

In respect to the former, in the first half of FY 2019 Cochlear delivered an increase in sales revenue of 11% and net profit of 16% compared to the prior corresponding period.

A key driver of this strong first half performance was the company's Services business which grew revenue by 28%.

At the time, Cochlear's CEO, Dig Howitt, explained: "The Services business continues to grow in importance as our recipient base grows, now representing almost 30% of sales revenue. Cochlear's recipients have enthusiastically embraced the Nucleus 7 Sound Processor, the world's first Made for iPhone cochlear implant sound processor, launched in October 2017, with the addition of the Nucleus Smart App for Android, released in June 2018."

This strong half led to management maintaining its FY 2019 net profit guidance of $265 million to $275 million, which will be an increase of 8% to 12% on FY 2018's result. And judging by its strong share price rally this year, investors appear confident that the company will be hitting the high end of its guidance range.

In addition to this strong performance, the company's shares were given a boost from news that it has received U.S. Food and Drug Administration (FDA) approval for the Nucleus Profile Plus Series cochlear implant.

Cochlear's Nucleus Profile Plus Series is the latest range of Nucleus implants that three decades worth of collaborative clinical and technical research work has created.

This latest implant has been designed for routine 1.5 and 3 Tesla magnetic resonance imaging scans without the need to remove the internal magnet. This means that users of the implant can undergo a scan such as an MRI without needing to remove the internal magnet or to apply a bandage and splint. This wasn't possible with previous implants, making the new implant much more manageable and convenient for its users.

Given this development and management's plan to develop a totally implantable cochlear implant in the future, Cochlear looks well-placed to take advantage of the expected increase in demand for hearing assistance over the next few decades as ageing populations expand across the globe.

Should you invest?

Whilst Cochlear's shares look fully valued at the current level and better entry points may emerge in the coming months, I would still be a buyer of its shares if you were planning to hold them for the next decade.

The same applies for fellow healthcare sector stars CSL Limited (ASX: CSL) and ResMed Inc. (ASX: RMD), which I think would also be great buy and hold options.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Person pointing at an increasing blue graph which represents a rising share price.
Growth Shares

What to buy now with the ASX at a record high

Analysts think these shares could still rise strongly from current levels.

Read more »

A young man looks at a stylised investment graph superimposed on an exterior office building backdrop.
Growth Shares

Where to invest $10,000 in ASX 200 stocks today

Analysts think these high-quality shares are in the buy zone for investors right now.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Growth Shares

Two ASX industrials shares with buy recommendations

One broker believes these growth shares are set to rise.

Read more »

Man smiling at a laptop because of a rising share price.
Growth Shares

I think these 2 exciting ASX growth shares are buys today

These stocks could deliver big returns.

Read more »

a man in a business suit and carrying a laptop stands smiling with hand in pocket outside a large office building in a city environment.
Growth Shares

Buy these 2 impressive ASX 200 shares in July: experts

Experts are bullish about these two businesses.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

3 ASX 200 shares set to dominate the next decade

Let's see why these shares could be great long term picks for Aussie investors.

Read more »

A group of businesspeople clapping.
Growth Shares

3 ASX growth shares with 10-year compounding potential

Let's see which shares are being tipped as buys for growth investors.

Read more »

Woman happy and relaxed on a sofa at a shop.
Growth Shares

Are these 2 top ASX growth shares buys?

Are these high-flyers still buys?

Read more »